Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 451-464

  Lee, Louisa C Y ^a   Maurice, Donald H ^b   Baillie, George S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZX 100; BETA ARRESTIN; CARDIOVASCULAR AGENT; CILOSTAMIDE; CYCLIC AMP; HEAT SHOCK PROTEIN 20; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; UNCLASSIFIED DRUG;

APOPTOSIS; BETA ADRENERGIC STIMULATION; CARDIOVASCULAR DISEASE; CELL COMPARTMENTALIZATION; CELL METABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEX FORMATION; DIARRHEA; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; EXCITATION CONTRACTION COUPLING; HEADACHE; HEART PROTECTION; HUMAN; NAUSEA; NONHUMAN; PANCREATITIS; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; VOMITING; WEIGHT REDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLIC AMP; HUMANS; MOLECULAR TARGETED THERAPY; PEPTIDES; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84875172143     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.216     Document Type: Review

References (122)

1. Blumenthal SA. Earl Sutherland (1915-1975) and the discovery of cyclic AMP. Perspect Biol. Med. 55(2), 236-249 (2012).
2. Beavo JA, Brunton LL. Cyclic nucleotide research-still expanding after half a century. Nat. Rev. Mol. Cell Biol. 3(9), 710-718 (2002).
3. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am. J. Respir. Cell Mol. Biol. 39(2), 127-132 (2008).
4. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12(6), 258-266 (2002).
5. Yamamizu K, Yamashita JK. Roles of cyclic adenosine monophosphate signaling in endothelial cell differentiation and arterial-venous specifcation during vascular development. Circ. J. 75(2), 253-260 (2011).
6. Alberini CM, Ghirardi M, Huang YY, Nguyen PV, Kandel ER. A molecular switch for the consolidation of long-term memory: cAMP-inducible gene expression. Ann. NY Acad. Sci. 758, 261-286 (1995).
7. 2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach'. Am. J. Physiol. Cell. Physiol. 294(1), C4-C6 (2008).
8. Lissandron V, Zaccolo M. Compartmentalized cAMP/PKA signalling regulates cardiac excitation-contraction coupling. J. Muscle Res. Cell Motil. 27(5-7), 399-403 (2006).
9. Baillie GS, Sood A, McPhee I et al. Beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-Adrenoceptor switching from Gs to Gi. Proc. Natl Acad. Sci. USA 100 (3), 940-945 (2003).
10. Bers DM. Cardiac excitation-contraction coupling. Nature, 415(6868), 198-205 (2002).
11. Li L, Desantiago J, Chu G, Kranias EG, Bers DM. Phosphorylation of phospholamban and troponin I in beta-Adrenergic-induced acceleration of cardiac relaxation. Am. J. Physiol. Heart Circ. Physiol. 278(3), H769-H779 (2000).
12. Pereira L, Ruiz-Hurtado G, Morel E et al. Epac enhances excitation-transcription coupling in cardiac myocytes. J. Mol. Cell. Cardiol. 52(1), 283-291(2012).
13. 2+ mobilization in cardiac myocytes. J. Biol. Chem. 282(8), 5488-5495 (2007).
14. Kraus-Friedmann N. Cyclic nucleotide-gated channels in non-sensory organs. Cell Calcium 27(3), 127-138 (2000).
15. Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J. Biol. Chem. 255(11), 5113-5119 (1980).
16. Brunton LL, Hayes JS, Mayer SE. Functional compartmentation of cyclic AMP and protein kinase in heart. Adv. Cyclic Nucleotide Res. 14, 391-397 (1981).
17. Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes. Mol. Interv. 10(2), 86-97 (2010).
18. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
19. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295 (5560), 1711-1715 (2002).
20. Baillie GS. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J. 276 (7), 1790-1799 (2009).
21. Feinstein W P, Zhu B, Leavesley SJ, Sayner SL, Rich TC. Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells. Am. J. Physiol. Cell. Physiol. 302(6), C839-C852 (2012).
22. Houslay MD, Baillie GS, Maurice DH. cAMP-Specifc phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res. 100(7), 950-966 (2007).
23. Troger J, Moutty MC, Skroblin P, Klussmann E. A-kinase anchoring proteins as potential drug targets. Br. J. Pharmacol. 166(2), 420-433 (2012).
24. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specifc therapeutic agents. Pharmacol. Ther. 109(3), 366-398 (2006).
25. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci. 31(12), 680-686 (2006).
26. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform mu ltipl icit y. Trends Biochem. Sci. 22(6), 217-224 (1997).
27. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58(3), 488-520 (2006).
28. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today. 10(22), 1503-1519 (2005).
29. Bolger GB, Baillie GS, Li X et al. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-Arrestin and RACK1, in cAMP-specifc phosphodiesterase PDE4D5. Biochem. J. 398(1), 23-36 (2006).
30. Bolger GB, McCahill A, Huston E et al. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-Arrestins. J. Biol. Chem. 278(49), 49230-49238 (2003).
31. Stefan E, Wiesner B, Baillie GS et al. Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J. Am. Soc. Nephrol. 18(1), 199-212 (2007).
32. Richter W, Day P, Agrawal R et al. Signaling from beta1-And beta2-Adrenergic receptors is defned by differential interactions with PDE4. EMBO J. 27(2), 384-393 (2008).
33. Bolger GB, Peden AH, Steele MR et al. Attenuation of the activity of the cAMP-specifc phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J. Biol. Chem. 278(35), 33351-33363 (2003).
34. Dodge-Kafka KL, Soughayer J, Pare GC et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437(7058), 574-578 (2005).
35. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem. J. 381(Pt 3), 587-592 (2004).
36. Beard MB, O'Connell JC, Bolger GB, Houslay MD. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specifc SH3 domains. FEBS Lett. 460(1), 173-177 (1999).
37. Collins DM, Murdoch H, Dunlop AJ et al. Ndel1 alters its conformation by sequestering cAMP-specifc phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA). Cell. Signal. 20(12), 2356-2369 (2008).
38. Sachs BD, Baillie GS, McCall JR et al. p75 neurotrophin receptor regulates tissue fbrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J. Cell Biol. 177(6), 1119-1132 (2007).
39. Millar JK, Pickard BS, Mackie S et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (5751), 1187-1191 (2005).
40. Terrenoire C, Houslay MD, Baillie GS, Kass RS. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J. Biol. Chem. 284 (14), 9140-9146 (2009).
41. Lee JH, Richter W, Namkung W et al. Dynamic regulation of cystic fbrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J. Biol. Chem. 282(14), 10414-10422 (2007).
42. 2+-triggered membrane association with selectivity for interaction with phosphatidic acid. J. Biol. Chem. 277(31), 28298-28309 (2002).
43. Grange M, Sette C, Cuomo M et al. The cAMP-specifc phosphodiesterase PDE4D3 is regulated by phosphatidic acid binding. Consequences for cAMP signaling pathway and characterization of a phosphatidic acid binding site. J. Biol. Chem. 275(43), 33379-33387 (2000).
44. Francis SH, Houslay MD, Conti M. Phosphodiesterase inhibitors: factors that infuence potency, selectivity, and action. Handb. Exp. Pharmacol. 204, 47-84 (2011).
45. Zhang KY, Ibrahim PN, Gillette S, Bollag G. Phosphodiesterase-4 as a potential drug target. Expert Opin. Ther. Targets. 9(6), 1283-1305 (2005).
46. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Rofumilast. Nat. Rev. Drug Discov. 9(10), 761-762 (2010).
47. Gupta S. Side-effects of rofumilast. Lancet 379(9817), 710-711; Author reply 711-712 (2012).
48. Lynch MJ, Baillie GS, Houslay MD. cAMP-specifc phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling. Biochem. Soc. Trans. 35(Pt 5), 938-941 (2007).
49. Lynch MJ, Baillie GS, Mohamed A et al. RNA silencing identifes PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta-Arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-Adrenergic receptor to activation of ERK in HEK293B2 cells. J. Biol. Chem. 280(39), 33178-33189 (2005).
50. McCahill A, McSorley T, Huston E et al. In resting COS1 cells a dominant negative approach shows that specifc, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell. Signal. 17(9), 1158-1173 (2005).
51. Bruss MD, Richter W, Horner K, Jin SL, Conti M. Critical role of PDE4D in beta2-Adrenoceptor-dependent cAMP signaling in mouse embryonic fbroblasts. J. Biol. Chem. 283(33), 22430-22442 (2008).
52. Smith KJ, Baillie GS, Hyde EI et al. 1H NMR structural and functional characterisation of a cAMP-specifc phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-Arrestin and RACK1. Cell. Signal. 19(12), 2612-2624 (2007).
53. Frank R. High-density synthetic peptide microarrays: emerging tools for functional genomics and proteomics. Comb. Chem. High Throughput Screen. 5(6), 429-440 (2002).
54. Sin YY, Edwards HV, Li X et al. Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the beta-Agonist induced hypertrophic response in cardiac myocytes. J. Mol. Cell. Cardiol. 50(5), 872-883 (2011).
55. Le Jeune IR, Shepherd M, Van Heeke G, Houslay MD, Hall IP. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identifcation and characterization of a novel PDE4D5 promoter. J. Biol. Chem. 277(39), 35980-35989 (2002).
56. Mongillo M, McSorley T, Evellin S et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res. 95(1), 67-75 (2004).
57. Willoughby D, Baillie GS, Lynch MJ, Ciruela A, Houslay MD, Cooper DM. Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during beta2-Adrenoceptor and prostanoid receptor cAMP signaling. J. Biol. Chem. 282(47), 34235-34249 (2007).
58. Trian T, Burgess JK, Niimi K et al. Beta2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D. PLoS ONE 6(5), e20000 (2011).
59. Perry SJ, Baillie GS, Kohout TA et al. Targeting of cyclic AMP degradation to beta 2-Adrenergic receptors by beta-Arrestins. Science 298(5594), 834-836 (2002).
60. Billington CK, Le Jeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 38, 1-7 (2008).
61. Shenoy SK, Lefkowitz RJ. beta-Arrestin-mediated receptor traffcking and signal transduction. Trends Pharmacol. Sci. 32(9), 521-533 (2011).
62. Fraser ID, Cong M, Kim J et al. Assembly of an A kinase-Anchoring protein-beta(2)-Adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr. Biol. 10(7), 409-412 (2000).
63. Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specifc phosphodiesterase PDE4D5 isoform. J. Biol. Chem. 274 (21), 14909-14917 (1999).
64. Serrels B, Sandilands E, Serrels A et al. A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr.Biol. 20(12), 1086-1092 (2010).
65. Aufricht C. HSP: helper, suppressor, protector. Kidney Int. 65(2), 739-740 (2004).
66. Mymrikov EV, Seit-Nebi AS, Gusev NB. Large potentials of small heat shock proteins. Physiol. Rev. 91 (4), 1123-1159 (2011).
67. Fan GC, Kranias EG. Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failure. J. Mol. Cell. Cardiol. 51(4), 574-577 (2010).
68. Edwards H V, Cameron RT, Baillie GS. The emerging role of HSP20 as a multifunctional protective agent. Cell. Signal. 23(9), 1447-1454 (2011).
69. Edwards H V, Scott JD, Baillie GS. PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects. Biochem. Soc. Trans. 40 (1), 210-214 (2012).
70. Edwards H V, Scott JD, Baillie GS. The A-kinase-Anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser16. Biochem J. 446(3), 437-443 (2012).
71. An SS, Askovich PS, Zarembinski TI et al. A novel small molecule target in human airway smooth muscle for potential treatment of obstructive lung diseases: a staged high-throughput biophysical screening. Respir. Res. 12(1), 8 (2011).
72. Willis MS, Patterson C. Hold me tight: role of the heat shock protein family of chaperones in cardiac disease. Circulation 122 (17), 1740-1751 (2010).
73. Fan GC, Yuan Q, Song G et al. Small heat-shock protein Hsp20 attenuates beta-Agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1. Circ. Res. 99(11), 1233-1242 (2006).
74. Fan GC, Chu G, Mitton B, Song Q, Yuan Q, Kranias EG. Small heat-shock protein Hsp20 phosphorylation inhibits beta-Agonist-induced cardiac apoptosis. Circ. Res. 94(11), 1474-1482 (2004).
75. Fan GC, Ren X, Qian J et al. Novel cardioprotective role of a small heat-shock protein, Hsp20, against ischemia/reperfusion injur y. Circulation. 111(14), 1792-1799 (2005).
76. Dreiza CM, Brophy CM, Komalavilas P et al. Transducible heat shock protein 20 (HSP20) phosphopeptide alters cytoskeletal dynamics. FASEB J. 19(2), 261-263 (2005).
77. Flynn CR, Brophy CM, Furnish EJ et al. Transduction of phosphorylated heat shock-related protein 20, HSP20, prevents vasospasm of human umbilical artery smooth muscle. J. Appl. Physiol. 98 (5), 1836-1845 (2005).
78. Dreiza CM, Komalavilas P, Furnish EJ et al. The small heat shock protein, HSPB6, in muscle function and disease. Cell Stress Chaperones, 15(1), 1-11 (2009).
79. Komalavilas P, Penn RB, Flynn CR et al. The small heat shock-related protein, HSP20, is a cAMP-dependent protein kinase substrate that is involved in airway smooth muscle relaxation. Am. J. Physiol. Lung. Cell Mol. Physiol. 294(1), L69-L78 (2008).
80. Kanno Y, Matsuno H. The possibility of novel antiplatelet peptides: the physiological effects of low molecular weight HSPs on platelets. Curr. Pharm. Des. 12(7), 887-892 (2006).
81. Lopes LB, Furnish EJ, Komalavilas P et al. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fbroblasts. J. Invest. Dermatol. 129(3), 590-598 (2009).
82. Fantidis P. The role of intracellular 3́5́-cyclic adenosine monophosphate (cAMP) in atherosclerosis. Curr. Vasc. Pharmacol. 8(4), 464-472 (2009).
83. Sayner SL. Emerging themes of cAMP regulation of the pulmonary endothelial barrier. Am. J. Physiol. Lung Cell. Mol. Physiol. 300(5), L667-L678 (2011).
84. Rampersad SN, Ovens JD, Huston E et al. Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J. Biol. Chem. 285(44), 33614-33622 (2010).
85. Wilson LS, Baillie GS, Pritchard LM et al. A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J. Biol. Chem. 286(18), 16285-16296 (2011).
86. Patrucco E, Notte A, Barberis L et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 118(3), 375-387 (2004).
87. Voigt P, Dorner MB, Schaefer M. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281(15), 9977-9986 (2006).
88. Metrich M, Lucas A, Gastineau M et al. Epac mediates beta-Adrenergic receptor-induced cardiomyocyte hypertrophy. Circ. Res. 102(8), 959-965 (2008).
89. Metrich M, Morel E, Berthouze M et al. Functional characterization of the cAMP-binding proteins Epac in cardiac myocytes. Pharmacol. Rep. 61(1), 146-153 (2009).
90. Metrich M, Laurent AC, Breckler M et al. Epac activation induces histone deacetylase nuclear export via a Ras-dependent signalling pat hway. Cell. Signal. 22 (10), 1459-1468 (2010).
91. Serrels B, Sandilands E, Frame MC. Signaling of the direction-sensing FAK/RACK1/PDE4D5 complex to the small GTPase Rap1. Small GTPases 2(1), 54-61 (2011).
92. McConnachie G, Langeberg LK, Scott JD. AKAP signaling complexes: getting to the heart of the matter. Trends Mol. Med. 12(7), 317-323 (2006).
93. Dodge-Kafka KL, Langeberg L, Scott JD. Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ. Res. 98(8), 993-1001 (2006).
94. Banky P, Newlon MG, Roy M, Garrod S, Taylor SS, Jennings PA. Isoform-specifc differences between the type Ialpha and IIalpha cyclic AMP-dependent protein kinase anchoring domains revealed by solution NMR. J. Biol. Chem. 275(45), 35146-35152 (2000).
95. Stokka AJ, Gesellchen F, Carlson CR, Scott JD, Herberg FW, Tasken K. Characterization of A-kinase-Anchoring disruptors using a solution-based assay. Biochem J. 400(3), 493-499 (2006).
96. Angelo R, Rubin CS. Molecular characterization of an anchor protein (AKAPCE) that binds the RI subunit (RCE) of type I protein kinase A from Caenorhabditis elegans. J. Biol. Chem. 273 (23), 14633-14643 (1998).
97. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. Identifcation of a novel protein kinase A anchoring protein that binds both type I and type II regulatory subunits. J. Biol. Chem. 272(12), 8057-8064 (1997).
98. Bauman AL, Soughayer J, Nguyen BT et al. Dynamic regulation of cAMP synthesis through anchored PKA-Adenylyl cyclase V/VI complexes. Mol. Cell 23(6), 925-931 (2006).
99. 2+-dependent cAMP synthesis in pancreatic and neuronal systems. J. Biol. Chem. 285(26), 20328-20342 (2010).
100. Gardner LA, Tavalin SJ, Goehring AS, Scott JD, Bahouth SW. AKAP79-mediated targeting of the cyclic AMP-dependent protein kinase to the beta1-Adrenergic receptor promotes recycling and functional resensitization of the receptor. J. Biol. Chem. 281(44), 33537-33553 (2006).
101. Dart C, Leyland ML. Targeting of an A kinase-Anchoring protein, AKAP79, to an inwardly rectifying potassium channel, Kir2.1. J. Biol. Chem. 276(23), 20499-20505 (2001).
102. Tavalin SJ, Colledge M, Hell JW, Langeberg LK, Huganir RL, Scott JD. Regulation of GluR1 by the A-kinase anchoring protein 79 (AKAP79) signaling complex shares properties with long-term depression. J. Neurosci. 22(8), 3044-3051 (2002).
103. Schnizler K, Shutov LP, Van Kanegan MJ et al. Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons. J. Neurosci. 28(19), 4904-4917 (2008).
104. Brandon NJ, Jovanovic JN, Colledge M et al. A-kinase anchoring protein 79/150 facilitates the phosphorylation of GABA(A) receptors by cAMP-dependent protein kinase via selective interaction with receptor beta subunits. Mol. Cell. Neurosci. 22(1), 87-97 (2003).
105. Carlson CR, Lygren B, Berge T et al. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J. Biol. Chem. 281(30), 21535-21545 (2006).
106. Faruque OM, Le-Nguyen D, Lajoix AD et al. Cell-permeable peptide-based disruption of endogenous PKA-AKAP complexes: a tool for studying the molecular roles of AKAP-mediated PKA subcellular anchoring. Am. J. Physiol. Cell Physiol. 296(2), C306-C316 (2009).
107. McConnell BK, Popovic Z, Mal N et al. Disruption of protein kinase A interaction with A-kinase-Anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J. Biol. Chem. 284 (3), 1583-1592 (2009).
108. Patel HH, Hamuro LL, Chun BJ et al. Disruption of protein kinase A localization using a trans-Activator of transcription (TAT)-conjugated A-kinase-Anchoring peptide reduces cardiac function. J. Biol. Chem. 285(36), 27632-27640 (2010).
109. Gold MG, Lygren B, Dokurno P et al. Molecular basis of AKAP specifcity for PKA regulatory subunits. Mol. Cell 24(3), 383-395 (2006).
110. Hundsrucker C, Klussmann E. Direct AKAP-mediated protein-protein interactions as potential drug targets. Handb. Exp. Pharmacol. 186, 483-503 (2008).
111. Mauban JR, O'Donnell M, Warrier S, Manni S, Bond M. AKAP-scaffolding proteins and regulation of cardiac physiology. Physiology 24, 78-87 (2009).
112. Hulme JT, Lin TW, Westenbroek RE, Scheuer T, Catterall WA. Beta-Adrenergic regulation requires direct anchoring of PK A to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-Anchoring protein 15. Proc. Natl Acad. Sci. USA 100(22), 13093-13098 (2003).
113. 2+ channel and modulates its function. J. Biol. Chem. 277(6), 4079-4087 (2002).
114. 2+ re-uptake into heart sarcoplasmic reticulum. EMBO Rep. 8(11), 1061-1067 (2007).
115. Schmitt JP, Kamisago M, Asahi M et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299 (5611), 1410-1413 (2003).
116. Haghighi K, Schmidt AG, Hoit BD et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J. Biol. Chem. 276(26), 24145-24152 (2001).
117. Bauman AL, Michel JJ, Henson E, Dodge-Kafka KL, Kapiloff MS. The mAKAP signalosome and cardiac myocyte hypertrophy. IUBMB Life 59 (3), 163-169 (2007).
118. Li J, Kritzer MD, Carlisle Michel JJ et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ. Res. 112(1), 128-139 (2012).
119. Christian F, Szaszak M, Friedl S et al. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J. Biol. Chem. 286(11), 9079-9096 (2011).
120. Lehnart SE, Wehrens XH, Reiken S et al. Phosphodiesterase 4D defciency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123(1), 25-35 (2005).
121. 2+ current. Circ. Res. 109 (9), 1024-1030 (2011).
122. Leroy J, Richter W, Mika D et al. Phosphodiesterase 4B in the cardiac L-type Ca(2)(+) channel complex regulates Ca(2)(+) current and protects against ventricular arrhythmias in mice. J. Clin. Invest. 121(7), 2651-2661 (2011).